Insights and Analysis
AI-washing – when AI hype becomes a litigation risk
Gibby Baker
Senior Associate Corporate & Finance
Gibby represents public and private companies on domestic and cross-border transactions, including mergers and acquisitions, asset purchases, joint ventures and other strategic collaborations. Gibby has worked with clients across a range of industries, with particular experience in the life sciences sector. Prior to joining Hogan Lovells, she earned simultaneous J.D. and M.B.A. degrees from Villanova University.
Represented Marvell Technology Group on its US$10bn acquisition of Inphi in a cash-and-stock transaction
Represented PeproTech, Inc., a leading developer and manufacturer of recombinant proteins, in its auction and subsequent $1.85 billion sale to Thermo Fisher Scientific Inc.
Represented Marinus Pharmaceuticals, Inc. in a two step tender offer followed by a merger with Immedica Pharma AB for $151 million
Represented a life sciences and health care contract manufacturing company in its sale to a leading manufacturer of consumer goods
Represented Sesen Bio, a clinical stage biopharmaceutical company, on its reverse merger with Carisma Therapeutics, a biopharmaceutical company focusing on cellular immunotherapy
Represented EyePoint Pharmaceuticals Inc. in its US$115m underwritten public offering of equity securities through a syndicate of underwriters led by Cowen and Gugenheim Securities